Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.047 AUD | 0.00% | 0.00% | -24.19% |
Mar. 25 | Transcript : Prescient Therapeutics Limited - Special Call | |
Feb. 23 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 1.89M 1.26M | Sales 2023 | 2.43M 1.61M | Capitalization | 65.23M 43.35M |
---|---|---|---|---|---|
Net income 2022 | -5M -3.32M | Net income 2023 | -7M -4.65M | EV / Sales 2022 | 47.2 x |
Net cash position 2022 | 12.28M 8.16M | Net cash position 2023 | 21.92M 14.56M | EV / Sales 2023 | 17.8 x |
P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-8.41
x | Employees | 3 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.49% |
Latest transcript on Prescient Therapeutics Limited
1 week | +2.17% | ||
Current month | +4.44% | ||
1 month | +2.17% | ||
3 months | +4.44% | ||
6 months | -48.35% | ||
Current year | -24.19% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-11-27 | |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Engle
CHM | Chairman | 69 | 14-11-27 |
James Campbell
BRD | Director/Board Member | - | 14-11-27 |
Ellen Feigal
BRD | Director/Board Member | 69 | 23-05-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 0.047 | 0.00% | 212 674 |
24-06-04 | 0.047 | 0.00% | 300,128 |
24-06-03 | 0.047 | +4.44% | 843,946 |
24-05-31 | 0.045 | 0.00% | 166,515 |
24-05-30 | 0.045 | -2.17% | 580,842 |
Delayed Quote Australian S.E., June 05, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-24.19% | 25.16M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.98% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- PTX Stock